SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is trending as investors aggressively rotate into CPU-related AI plays following positive sector sentiment and optimistic analyst upgrades. The community is sharply divided, with bulls pointing to long-term secular growth and infrastructure dominance while bearish traders voice concerns over extreme valuation multiples, extended RSI levels, and the sustainability of this rapid parabolic move.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining significant traction as a community-driven meme project that emphasizes rapid, collective "sending" to build momentum toward its market cap goals. The community is heavily focused on HODLing through volatility, active promotion to onboard new degens, and community-wide airdrops to reward early supporters as they aim to hit key milestones.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently surging due to the FDA lifting the clinical hold on its Phase 3 MAGNITUDE trial, signaling a significant derisking of its CRISPR-based heart disease therapy. Community discussion is dominated by bullish sentiment regarding the potential for a major short squeeze, as participants highlight the stock's high short interest and the significant valuation gap remaining since the trial's original halt.

"What's Updog?" is a Community Led token.

UpDog

UpDog is capturing attention through a combination of sustained community momentum, aggressive whale accumulation, and successful organic growth efforts that have kept the token trending. Investors are actively discussing the project's multi-year history on Solana and its presence on the Jupiter strict list, with many looking for the next major leg up in its market trajectory.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened market attention as community members speculate on potential supply burns and project revivals while actively monitoring upcoming clarity legislation. Investors are engaging in spirited discussions regarding the token's long-term utility, with many holding positions in anticipation of a significant price reversal.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as a major retail and momentum favorite, fueled by significant investor enthusiasm over potential partnerships with hyperscalers and its role in AI data center infrastructure. The community is heavily focused on a potential short squeeze, given the intense trading volume and reports of restricted share availability, while debates persist between optimistic long-term holders and bearish concerns regarding the company's current revenue levels.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a historic surge, fueled by an earnings beat that shifted investor sentiment on the role of CPUs in AI infrastructure and triggered a massive short squeeze. The community is actively debating the sustainability of this parabolic move, with many traders watching closely for a potential pullback while bulls point to new foundry partnerships and deep-pocketed institutional backing as evidence of a long-term turnaround.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera Inc. is trending as investors aggressively speculate on imminent partnership announcements following a series of technical advancements in semiconductor materials. Community sentiment is deeply divided between long-term supporters anticipating a major licensing breakthrough and vocal critics expressing skepticism over the firm's long-standing lack of commercial revenue.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing heightened investor attention as the semiconductor sector navigates the complex intersection of AI-driven demand and supply-side constraints. Community discussions are centered on the company's long-term potential in edge AI and automotive markets versus short-term concerns regarding memory shortages and shifting handset industry dynamics.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing a massive rally driven by insatiable AI data center demand for high-performance NAND flash memory and anticipation surrounding its upcoming earnings. The community is actively tracking a potential stock split, while retail investors remain locked in a heated debate between holding for further parabolic gains and betting on an inevitable correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Under the new rule, Hospital Outpatient Department (HOPD) reimbursement for Nyxoah’s Genio hypoglossal nerve stimulation implants will increase to approximately $45,000 starting in 2026.</li><li>According to Nyxoah, the Genio procedure is well-suited for the ASC environment, and the new rules create new opportunities for site-of-service diversification as well.</li></ul>Shares of Nyxoah SA (NYXH) jumped 7% in the pre-market session on Wednesday after the company said that its Genio Therapy would benefit from the new medicare reimbursement criteria for CY2026.The U.S. Centers for Medicare &amp; Medicaid Services (CMS) finalized its CY2026 medicare reimbursement rules on Friday.<h2 class="st-heading-2">How Will It Aid Nyxoah?</h2>Under the new rule, Hospital Outpatient Department (HOPD) reimbursement for Nyxoah’s Genio hypoglossal nerve stimulation implants for the treatment of Obstructive Sleep Apnea will increase to approximately $45,000 starting in 2026, a 48% rise compared to 2025, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/26/3194857/0/en/Nyxoah-s-Genio-Therapy-Receives-Significant-2026-Medicare-Reimbursement-Increases-Under-Final-CMS-Rule.html">said</a>. Ambulatory Surgery Centers (ASC) facility reimbursement, meanwhile, will increase to $42,373, reflecting a 58% increase compared to 2025.Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions. Further, the procedure is well-suited for the ASC environment, and the change in rules creates new opportunities for therapy expansion and site-of-service diversification, the company added.<h2 class="st-heading-2">Others To Benefit From New Rules</h2>The new rules apply to Nyxoah’s peers, too. Earlier this week, Stifel analyst Jonathan Block upgraded Inspire Medical Systems (INSP) to ‘Buy’ from ‘Hold’ while also hiking the price target to $110, up from $100.Inspire Medical makes the Inspire V implant to treat obstructive sleep apnea. It is installed in an approximate 60-minute outpatient procedure. According to the Stifel analyst, the company's headwinds are easing following CMS's positive reimbursement revision on Friday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NYXH fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:624/60;" src="data:image/png;base64,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" width="624" height="60" alt="NYXH’s Sentiment Meter and Message Volume as of 7:56 a.m. ET on Nov. 26, 2025 | Source: Stocktwits"><figcaption>NYXH’s Sentiment Meter and Message Volume as of 7:56 a.m. ET on Nov. 26, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/NYXH">NYXH stock</a> fell 43% this year and by about 44% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/bytedance-reportedly-tops-chinese-nvidia-chip-buyers-but-now-it-can-t-use-them/cL53FkSREWe">Bytedance Reportedly Tops Chinese Nvidia Chip Buyers – But Now It Can't Use Them</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Natalie Boller, 63, has a Genio Nyxoah bilateral hypoglossal nerve stimulator implant fitted for obstructive sleep apnoea. Picture date: Wednesday December 4, 2024. (Photo by Lucy North/PA Images via Getty Images)

Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy

Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions.

Equity

<ul class="summary-bullets"><li>Aucatzyl will be available through routine commissioning by the NHS, the company said.</li><li>Aucatzyl was approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in November 2024.</li><li>The company also intends to launch Aucatzyl in England and Wales soon, It added.</li></ul> Autolus Therapeutics Plc (AUTL) said on Tuesday that the UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance recommending its Aucatzyl CAR T cell therapy for use in the National Health Service (NHS) in England and WalesShares of the company rose 14% in the premarket session at the time of writing.<h2 class="st-heading-2">UK Approval And Recommendation</h2>NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://autolus.gcs-web.com/news-releases/news-release-details/nice-recommends-aucatzylr-obecabtagene-autoleucel-treatment">said</a>. Relapsed or refractory B-cell precursor acute lymphoblastic leukemia is a cancer that either returns after treatment or never responded to initial therapy.Aucatzyl will be available through routine commissioning by the NHS, the company said. The company also intends to launch Aucatzyl in England and Wales soon, it added.Aucatzyl or obecabtagene autoleucel is an autologous CD19 CAR T cell therapy. Autologous CD19 CAR T-cell therapy is an immunotherapy that uses a patient's own T-cells, which are genetically modified to target and attack cells that express the CD19 protein. This treatment has shown high efficacy in relapsed or refractory B-cell malignancies.The U.S. Food and Drug Administration approved Aucatzyl for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in November 2024. A conditional marketing authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) followed in April 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AUTL stayed within the ‘bearish’ territory over the past 24 hours, while message volume jumped from ‘low’ to ‘normal’ levels.A Stocktwits user sees the stock hitting as high as $2.50.<stembedurl>https://stocktwits.com/nader_1/message/637361441</stembedurl>Another applauded the recent announcement and expressed hope that cell therapy would become the standard of care.<stembedurl>https://stocktwits.com/janed102/message/637360741</stembedurl><a href="https://stocktwits.com/symbol/AUTL">AUTL stock</a> is down by 47% this year and by about 58% over the past 12 months. &nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-keys-stock-surge-14-in-premarket-today/cL52hzFREX8">Why Did KEYS Stock Surge 14% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK

NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said. 

Nasdaq-listed shares of Nyxoah SA (NYXH) soared 13% on Monday morning after the company announced that the first U.S commercial patients with Obstructive Sleep Apnea (OSA) have been successfully implanted with its Genio system.OSA is a common sleep disorder where the upper airway repeatedly collapses during sleep, leading to breathing pauses. It is associated with increased mortality risk and comorbidities, including cardiovascular diseases, depression, and stroke.Nyxoah’s Genio therapy is a mask-free treatment option and works by gently stimulating hypoglossal nerves to contract muscles on both sides of the tongue, keeping the airway open throughout the night. The Genio System features a battery-free stimulator that’s externally powered by a sleep wearable, with customizable settings. It provides an alternative to CPAP therapy, which uses a machine to deliver pressurized air through a mask, keeping the airway open during sleep and preventing breathing pauses.Nyxoah CEO Olivier Taelman said that the company has also trained surgeons, obtained Value Analysis Committee (VAC) approvals, and achieved successful coverage from major payors.“What's also particularly encouraging is the strong demand we're seeing from physicians, with surgeons actively reaching out for training opportunities, many of whom already have patients lined up for implants,” he <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.nyxoah.com/press-releases">added</a>.The Genio system received approval from the U.S. Food and Drug Administration in August for a subset of patients with moderate to severe OSA. The approval was supported by a trial that demonstrated Genioi’s efficacy regardless of a patient's sleeping position.<a href="https://stocktwits.com/symbol/NYXH">NYXH stock</a> is down by 30% this year and by about 40% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/adobe-expects-us-holiday-online-sales-to-reach-253-4-billion-this-year/ch6R3KNR3gh">Adobe Expects US Holiday Online Sales To Reach $253.4 Billion This Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

US-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep Disorder

Nyxoah CEO Olivier Taelman said that the company has also trained surgeons, obtained Value Analysis Committee approvals, and achieved successful coverage from major payors.

Current Price	$28.20
Prev Close	$28.40
Open	$28.19
Dividend Yield	N/A
50-Day Moving Average	$29.41
Beta	N/A
Avg. Volume	2,643.53
PE Ratio	N/A

52-Week High	$32.19
52-Week Low	$23.23
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

BMED
iShares Health Innovation Active ETF

Feed

News

Sentiment

Fundamentals

Info

Latest BMED News

BMEDiShares Health Innovation Active ETF